Latest News and Press Releases

Mainz Biomed Expands into Switzerland with labor team w

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

Mainz Biomed Announces Stock Split

Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update